BullScope
  • Home
  • Market News
  • Bargains & Bubbles
  • Expectations Audits
  • Research Notes
  • Said vs. Filed
  • The Economy
  • Evidence Sheets
  • Research Terminal
No Result
View All Result
SUBSCRIBE
BullScope
  • Home
  • Market News
  • Bargains & Bubbles
  • Expectations Audits
  • Research Notes
  • Said vs. Filed
  • The Economy
  • Evidence Sheets
  • Research Terminal
No Result
View All Result
BullScope
No Result
View All Result
Home Market News

Coca-Cola’s operating margin expands to 33.4% as pricing and volume gains offset cost pressures

Moe Alsumidaie by Moe Alsumidaie
October 28, 2026
in Market News
0
74
SHARES
1.2k
VIEWS
Share on XShare on LinkedInShare on Facebook

Coca-Cola raised full-year guidance after third-quarter net revenues grew 7% to $13.4 billion and operating margin expanded 140 basis points to 33.4%, driven by 5% unit case volume growth and pricing that more than offset higher marketing spend and operating expenses.

Net revenues reached $13.4 billion, up 7% from the prior year, with organic revenue growth of 7% split between a 7% increase in concentrate sales and 1% growth in price and mix. Operating income grew 12% on a reported basis; comparable currency-neutral operating income, which strips out one-time items and currency effects, grew 8%. The company’s operating margin of 33.4% compared to 32.0% in the prior year represents a 140-basis-point expansion. On a comparable basis excluding currency tailwinds and one-time items, the margin reached 32.9% versus 31.9%, a 100-basis-point gain. Earnings per share grew 8% to $0.93; comparable EPS grew 11% to $0.91, with a 2-point currency tailwind embedded in both figures.

Unit case volume, the measure of physical beverage consumption, grew 5% globally, led by India, China, Mexico and Brazil. Trademark Coca-Cola grew 5% and Coca-Cola Zero Sugar accelerated to 16% growth. Within categories, sparkling soft drinks grew 5%, water grew 8%, and sports drinks declined 3%. The company gained value share in total nonalcoholic ready-to-drink beverages on a consolidated basis. Year-to-date free cash flow reached $11.4 billion.

What it means

The margin expansion signals that Coca-Cola’s pricing power is outpacing its cost inflation. The company raised prices 1% while unit volumes grew 5%, meaning the company sold more units at higher prices. Concentrate sales grew 7%, outpacing the 5% unit case volume growth by 2 points due to timing of shipments to bottlers. The comparable operating margin gain of 100 basis points came despite an increase in marketing investments and higher operating expenses, suggesting that organic revenue growth and lower input costs in some regions (notably EMEA and Latin America) more than offset those headwinds.

BullScope TerminalYou just read COCA COLA CO’s filed numbers.Every claim above traces to a filing. Run any of 500+ companies through the same math-vs-mood engine. Free tier available.Open the Terminal →

Geography matters here. Latin America’s comparable currency-neutral operating income grew 14%, driven by both organic revenue growth and lower operating expenses, while the region’s price-mix jumped 7%. North America, by contrast, saw unit case volume flat at 0%, with volume declines in water, sports, coffee and tea offsetting Trademark Coca-Cola growth. Asia Pacific’s comparable currency-neutral operating income grew 14% despite a 3-point currency headwind, suggesting strong underlying operational performance. The Bottling Investments segment reported a 252% comparable currency-neutral operating income increase, though the document does not detail the driver.

The open question is whether the 1% price-mix gain is sustainable or whether it reflects a one-time benefit from prior pricing actions now lapping easier comparisons. The document states that price-mix was “primarily driven by pricing actions in the marketplace, partially offset by unfavorable mix,” which suggests the company is trading volume for margin in some categories. The North America flat volume and the sports drinks decline of 3% globally hint at elasticity constraints, though the company’s overall 5% volume growth and share gains in total NARTD beverages suggest pricing has not yet priced out material demand.

What to watch

The company raised full-year guidance, but the document does not state the new targets. Watch for the full earnings release or investor call on or after October 27, 2026, to see the revised annual revenue, operating income and EPS guidance and management’s commentary on whether North America volume pressure and sports drink weakness are temporary or structural.

Source: the company’s 8-K filed 2026-10-27 with the SEC.

BullScope publishes impersonal research for a general audience. Nothing here is personalized investment advice, and nothing here is a recommendation to buy or sell any security. As of publication, neither BullScope nor its operator holds a position in any security, covered or otherwise; we do not trade at all, and we accept no compensation from any company we cover. When a conflict of interest exists, we do not publish: companies that compensate our operator in any capacity, or about which our operator could hold nonpublic information, are barred from coverage automatically, as described in the conflicts policy in our methodology. Figures come from company filings and public data through our published methodology; forecasts are conditional scenarios, not predictions and not promises. Markets carry risk, including loss of principal. Consider your own situation, or consult a licensed adviser, before acting on anything you read.

For the standing yardsticks on Coca Cola: the price tag, the filed record, and the four gauges, refreshed with each edition, see the BullScope Evidence Sheet: Coca Cola.

BullScope TerminalYou just read COCA COLA CO’s filed numbers.Every claim above traces to a filing. Run any of 500+ companies through the same math-vs-mood engine. Free tier available.Open the Terminal →
Moe Alsumidaie

Moe Alsumidaie

Moe Alsumidaie, MBA, MSF, is founder and Chief Editor of Vanguard Publications, which publishes Clinical Trial Vanguard, Pharma Vanguard and BullScope, and Head of Research at CliniBiz. He has two decades in clinical trial operations and data science, with earlier roles at Genentech, Abbott Vascular and Stanford University Medical Center, and is a guest lecturer in clinical trial sciences at Rutgers University.

Recommended For You

Zoetis narrows revenue outlook as U.S. companion animal sales slide, raises profit guidance on margin strength

by Moe Alsumidaie
November 6, 2026
0

Zoetis cut its full-year revenue forecast to $9.220 billion to $9.320 billion, representing organic operational decline of 2 percent to 1 p

Read moreDetails

Viatris Raises 2026 Guidance as Adjusted EBITDA Climbs 9 Percent Year to Date

by Moe Alsumidaie
November 6, 2026
0

Viatris raised the midpoints of its full-year 2026 financial guidance across all key metrics on the strength of nine-month adjusted EBITDA

Read moreDetails

Joby Aviation raises FY26 revenue outlook 15% as eIPP flights and defense contracts accelerate path to certification

by Moe Alsumidaie
November 5, 2026
0

Joby Aviation lifted its full-year 2026 revenue guidance by 15 percent and completed the first crewed eVTOL flights under the federal gover

Read moreDetails

Amgen’s revenue growth slows to 8% as biosimilar competition erodes legacy franchises

by Moe Alsumidaie
November 4, 2026
0

Amgen's third-quarter revenue rose 8% to $10.4 billion, a deceleration from the 10.0% full-year growth rate filed for fiscal 2025. The slow

Read moreDetails

Palantir’s U.S. commercial revenue overtakes government for the first time as quarterly sales accelerate to 96% growth

by Moe Alsumidaie
November 3, 2026
0

Palantir Technologies raised full-year revenue guidance to 91% growth after U.S. commercial revenue surpassed U.S. government revenue in th

Read moreDetails
Next Post

Visa's revenue growth accelerates to 15% as cross-border volume and data processing outpace payments

Please login to join discussion
BullScope
The Research Terminal
Run any stock through the BullScope evidence engine. Filings in, evidence out. Every number explains itself.
Open the Terminal
A BullScope product

Related News

Who Holds the IOU Holds the Vote

August 29, 2026

Biogen’s stock has climbed 65% in a year. Its earnings have not.

September 28, 2026

Nike at $39: The Price That Doesn’t Match the Brand, or the Math

September 14, 2026
BullScope

BullScope is an evidence-first investment research publication. Every note starts in the filings: what companies actually report, what the market assumes, and where the two disagree. We read the numbers so you can read the story. Not investment advice.

Prefer BullScope.ai on Google

© 2026 BullScope. Evidence-first investment research. Not investment advice.  ·  Methodology  ·  Privacy Policy  ·  Terms of Use  ·  Disclaimer

No Result
View All Result
  • Home
  • Market News
  • Bargains & Bubbles
  • Expectations Audits
  • Research Notes
  • Said vs. Filed
  • The Economy
  • Evidence Sheets
  • Research Terminal

© 2026 BullScope. Evidence-first investment research. Not investment advice.  ·  Methodology  ·  Privacy Policy  ·  Terms of Use  ·  Disclaimer

Not enough quota to unlock this post
Unlock left : 0
Are you sure want to cancel subscription?
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.